Aurora Health Care Southern Lakes, INC.
Aurora Health Care Southern Lakes, INC. was paid $4.49M by Medicaid between Jan 2018 and Dec 2024, across 167 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 15% of everything it billed.
33Billing provider infoAURORA HEALTH CARE SOUTHERN LAKES, INC.
SUMMIT, WI 53066
SUMMIT, WI 53066
33aNPI1699008029assigned 09/17/2009
33bProvider typeOccupational Therapist
28Total paid$4.49M
24GClaims202,308
24DCodes billed167
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Occupational Therapist providers in Wisconsin
Rank by total paid#4 of 43
Median peer was paid$26K
This provider vs. median172×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,620 | $482K | |
| 2019 | 22,144 | $482K | |
| 2020 | 20,091 | $469K | |
| 2021 | 31,871 | $658K | |
| 2022 | 34,875 | $744K | |
| 2023 | 40,224 | $864K | |
| 2024incomplete | 32,483 | $787K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 15% | 18,760 | 7,246 | $683K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 8,055 | 7,184 | $504K |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.1% | 3,200 | 2,687 | $409K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.6% | 6,963 | 6,117 | $387K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.1% | 3,841 | 3,437 | $229K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 4.4% | 8,289 | 3,470 | $195K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.7% | 5,991 | 3,425 | $167K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 1,844 | 1,664 | $139K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.1% | 2,810 | 1,176 | $139K |
| 80053 | Comprehensive metabolic panel | 2.5% | 7,346 | 5,892 | $110K |
| 97161 | 2.4% | 2,673 | 2,482 | $108K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 1,624 | 1,469 | $104K |
155 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.3% | 1,174 | $104K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 1,254 | $93K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.7% | 2,567 | $76K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 10,542 | $71K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 881 | $66K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 250 | $58K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.3% | 1,451 | $58K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,814 | $44K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 680 | $35K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,487 | $35K |
| 84484 | <1% | 2,706 | $33K | |
| 81025 | <1% | 2,791 | $32K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 693 | $30K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,318 | $28K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 613 | $28K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 297 | $28K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 380 | $27K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 320 | $24K |
| 76830 | Ultrasound, transvaginal | <1% | 655 | $22K |
| 97162 | <1% | 522 | $20K | |
| 82077 | <1% | 875 | $20K | |
| 82962 | <1% | 2,062 | $18K | |
| 83735 | <1% | 3,160 | $17K | |
| 83690 | <1% | 2,567 | $15K | |
| 86850 | <1% | 708 | $14K | |
| 80047 | <1% | 759 | $14K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 681 | $13K |
| 74018 | <1% | 684 | $12K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 398 | $12K |
| 97597 | <1% | 420 | $11K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 218 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 966 | $11K |
| 76642 | <1% | 338 | $11K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 112 | $10K |
| 97165 | <1% | 271 | $9K | |
| 83880 | <1% | 283 | $9K | |
| 97116 | <1% | 625 | $9K | |
| G0378 | Hospital observation service, per hour | <1% | 473 | $8K |
| 81001 | <1% | 2,338 | $8K | |
| 85610 | <1% | 1,531 | $8K | |
| 81003 | <1% | 1,416 | $7K | |
| 97035 | <1% | 559 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 71 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,464 | $7K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 96 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 135 | $6K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 16 | $6K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 13 | $6K |
| 73630 | <1% | 341 | $5K | |
| 72141 | <1% | 64 | $5K | |
| 97803 | <1% | 440 | $5K | |
| 83605 | <1% | 536 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 56 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 152 | $4K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 465 | $4K |
| 76536 | <1% | 117 | $4K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 14 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 68 | $4K |
| 86900 | <1% | 767 | $4K | |
| 85379 | <1% | 378 | $3K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 15 | $3K |
| 93971 | <1% | 112 | $3K | |
| 84702 | <1% | 215 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,374 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 21 | $3K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 28 | $3K |
| 93975 | <1% | 69 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,256 | $2K |
| 72100 | <1% | 161 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 216 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 56 | $2K |
| 71250 | <1% | 63 | $2K | |
| 97166 | <1% | 57 | $2K | |
| 86901 | <1% | 767 | $2K | |
| 80143 | <1% | 131 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 62 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,930 | $1K |
| 85730 | <1% | 252 | $1K | |
| 93356 | <1% | 12 | $1K | |
| 0240U | <1% | 40 | $1K | |
| 80179 | <1% | 98 | $1K | |
| 84145 | <1% | 56 | $1K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 29 | $926.09 |
| 82803 | <1% | 45 | $849.69 | |
| 85027 | <1% | 198 | $800.30 | |
| 93017 | <1% | 14 | $763.42 | |
| 80076 | <1% | 90 | $749.68 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $720.79 |
| 73030 | <1% | 88 | $679.82 | |
| 73562 | <1% | 59 | $669.66 | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 12 | $637.11 |
| 92523 | <1% | 17 | $618.39 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,154 | $556.15 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12 | $530.18 |
| 77065 | Tomosynthesis, mammo | <1% | 58 | $513.77 |
| 73502 | <1% | 30 | $468.01 | |
| 82565 | <1% | 65 | $442.60 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,617 | $441.31 |
| 87040 | <1% | 31 | $420.86 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 16 | $369.00 |
| 87070 | <1% | 53 | $255.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,153 | $198.69 |
| 87205 | <1% | 67 | $188.10 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 17 | $177.63 |
| 87077 | <1% | 30 | $151.93 | |
| 86140 | <1% | 34 | $128.77 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,084 | $128.67 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,663 | $79.84 |
| 87186 | <1% | 14 | $71.70 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 16 | $70.26 |
| 85014 | <1% | 41 | $67.20 | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $66.00 |
| 83615 | <1% | 14 | $54.76 | |
| 96376 | <1% | 812 | $46.72 | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,069 | $35.38 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,154 | $34.94 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 31 | $31.36 |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | <1% | 17 | $13.16 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,792 | $11.13 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,345 | $8.82 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 145 | $8.18 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,679 | $7.96 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,643 | $5.98 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,189 | $1.25 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 3,031 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 321 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 1,354 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 3,287 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 39 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 270 | $0.00 |
| C1769 | Guide wire | 0% | 220 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 226 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 84 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 18 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 31 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 58 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 16 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 51 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 39 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 826 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 29 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 947 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 210 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 25 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 615 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 218 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 109 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 19 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 81 | $0.00 |
| 73610 | 0% | 14 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 51 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 17 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 13 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 15 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, KARA (VP MANAGED HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.